Skip to content
thestock.space

On 6 Nov 2026, Molbio Diagnostics was priced at ₹1,339.30, or 92.6× trailing earnings, against an industry P/E of 34.9×, and the shares are 21% below their 52-week high. It earns ROCE of 17% and ROE of 16%, and sales grew 64% a year over 3 years. Debt is 0.34× equity. It is a small-cap company with a market cap of ₹15,434 Cr, the largest of 9 Medical Devices companies by market cap; the shares rose 29% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹1,350.00
Day high
₹1,378.00
Day low
₹1,250.00
Prev. close
₹1,403.50
Volume
9.9 L

Health check

4 fair · 2 to check
  • ReturnsIn line

    +28.6% over a year, better than 3 of 7 peers.

  • Price tagPricier

    P/E 92.6 vs industry 34.9.

  • GrowthSteady

    Sales +63.7% a year over 3 years.

  • ProfitabilityAverage

    ROCE 16.5% vs peer median 12.9%.

  • Balance sheetFair

    Debt 0.34× equity, interest covered 8.4×, Piotroski 5 of 9.

  • Red flags1 to check

    P/E of 92.6 against an industry P/E of 34.9.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Devices

8 listed peers. Screen the industry

Small cap

₹15,434 Cr, the largest of 9 in its industry.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹1,754 Cr · profit ₹249 Cr
Market cap
₹15,434 Cr
Small cap
P/E
92.6
Industry 34.9
Price to book
12.91
Peers 2.85
Dividend yield
0.00%
ROE
15.6%
Peers 10.7%
ROCE
16.5%
Peers 12.9%
Debt to equity
0.34
Debt ₹450 Cr
EPS (TTM)
₹14.46
Face value ₹1
OPM (TTM)
20.4%
Net margin 14.2%
Sales growth
+309.6%
Latest quarter vs a year ago
Profit growth
n/a
Year-ago quarter not reported
Price to sales
8.80
EV/EBITDA 36.0

Strengths and risks

Strengths

  • Quarterly sales up 309.6% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • P/E of 92.6 against an industry P/E of 34.9.

Derived automatically from reported figures. Not a recommendation.

About Molbio Diagnostics

Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or…

Headquarters
Verna
Employees
1,225
Sector
Healthcare
ISIN
INE869T01028
Website
molbiodiagnostics.com

Price range

52 weeks

₹926.35₹1,686.80

Today

₹1,250.00₹1,378.00
Avg volume (3M)
29 L
1-year return
plus 28.6%
From 52-week high
minus 20.6%

Peers · Medical Devices

Compare with peersScreen the whole industry
Company
MOLBIOMolbio Diagnostics1,339.30minus 4.57%15,43492.612.9116.5%15.6%20.4%63.7%–0.00%plus 28.6%
SMTSahajanand Medical Technologies525.95plus 7.83%5,34677.37.4213.3%10.7%8.4%––0.00%plus 39.3%
FISCHERFischer Medical Ventures24.30minus 2.88%1,69810.44.0812.5%8.9%12.5%1097.3%–0.21%minus 73.4%
HSILHemant Surgical Industries628.65minus 0.21%91442.15.9519.5%18.1%10.0%28.4%33.5%0.00%plus 117.2%
UNIVPHOTOUniversus Photo Imagings480.00minus 1.49%525–0.65−9.5%−9.5%5.4%−24.3%–0.00%plus 74.8%
NURECANureca302.30minus 0.30%30261.41.53–2.5%8.3%9.7%–0.00%plus 17.4%
EARKARTEarkart111.00minus 5.13%15327.82.3712.1%11.7%15.3%23.2%55.5%0.00%minus 48.5%
CHOKSIChoksi Asia210.35minus 0.71%12023.12.8518.4%13.5%14.5%309.2%–0.00%plus 99.0%
Median of 7 peers–−0.71%52534.92.8512.9%10.7%10.0%25.8%44.5%0.00%39.3%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Jun 26
99.7408
115308
−15.3101
−15.3%24.6%
−0.13.1
3.610.7
12.317.1
−31.375.9
23.4%30.5%
−23.758.7
-2.065.10

Sep 25, Dec 25, Mar 26 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+63.7%
ROE
15.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3228209971,415
–+154.2%+21.7%+41.9%
2776357241,072
45.3184273343
14.0%22.5%27.4%24.2%
4.373.8−0.5−2.5
6.613.71631.4
31.74144.663.6
−1.7−73.8−18−14.4
9.5130194231
136.1%35.6%28.7%29.0%
−0.7102145167
––+42.3%+14.8%
-0.068.8512.5914.46

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2.32.32.311.3
7198219661,158
119184147450
194214346529
1,0341,2211,4622,148
200187277319
34.844.215.8
30.723.328.576.3
7.212.8129371
7949939831,366
1,0341,2211,4622,148

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
64.19.628750.4
−39.7−45−123−93.2
18.2−31.6−26.1276
42.6−67138233
−14.5−16.1−54.7−50
49.6−6.52320.4

Shareholding pattern

Source: NSE filings
41.3%
promoters
  • Promoters41.29%
  • Public58.71%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202641.29%58.71%0.00
14 Aug 202641.29%58.71%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you